Background: Despite the significant advances in surgical techniques and multimodality treatments for esophageal cancer, the overall survival remains unsatisfactory. During the past years, efforts were made to determine the prognostic factors that would help in identifying patients suitable for surgery or guiding adjuvant therapy. Positive circumferential resection margins (CRMs) in esophageal cancer have been previously linked with poor prognosis, but their impact on survival remains controversial in patients treated by a multimodality protocol. The aim of our study was to examine the significance of tumor involvement of CRM in patients with esophageal squamous cell carcinoma after concurrent chemoradiation therapy followed by esophagectomy. Methods: Between 2000 and 2010, 94 esophageal squamous cell carcinoma patients who received preoperative concurrent chemoradiation therapy followed by surgery were enrolled in our study. We focused on the CRM, which was defined microscopically as clear (negative) or involved (positive). Univariate and multivariate survival analyses were performed with overall survival as the endpoint. Results: Our cohort was predominantly male (94.7%) with a median age of 57 years. All of them received concurrent chemoradiation therapy followed by esophagectomy. Overall, 17 patients (18.1%) had positive CRM. KaplaneMeier survival analysis demonstrated that the 5-year overall survival of patients with clear and involved CRM is 60.1% and 11.8%, respectively (log rank p < 0.001). Multivariate analysis with the Cox proportional hazard model demonstrated that CRM involvement is a significant prognostic factor for overall survival ( p < 0.001). Conclusion: In patients with esophageal squamous cell carcinoma who underwent trimodality treatment, CRM involvement is a significant risk factor predicting survival. Additional effort is required to achieve a clear CRM in esophageal cancer treatment.
Introduction
Esophageal cancer is notorious for its highly malignant nature worldwide. Despite significant advances in surgical techniques and multimodality treatment in esophageal cancer, the prognosis after treatment remains poor. Positive circumferential resection margins (CRMs) in esophageal cancer have been previously demonstrated to be related to prognosis, but their impact on survival remains controversial. 1e9 Because esophageal cancer varies in both epidemiology and treatment modalities used, no standardized treatment protocol has been universally adopted. In addition to surgery, multimodality treatment including chemotherapy, radiation therapy, or concurrent chemoradiation therapy (CCRT) as neoadjuvant or adjuvant therapy has been established in many trials. Published studies on CRM of esophageal cancer have focused mainly on esophageal adenocarcinoma (ADC). The treatment mostly consisted of surgery alone or neoadjuvant chemotherapy.
1e9 However, the impact of CRM on survival has been uncertain in trimodality treatment of patients with esophageal squamous cell carcinoma (ESCC).
The purpose of our study was to investigate the significance of microscopic tumor involvement of CRM on long-term survival in a setting of trimodality treatment of patients with ESCC.
Methods

Patients and trimodality treatment
We retrospectively reviewed the medical records of consecutive 185 patients with esophageal cancer after esophagectomy in Koo Foundation Sun-Yat Sen Cancer Center (KF-SYSCC) between December 1999 and December 2010. The Institutional Review Board of KF-SYSCC approved this study and granted a waiver of the inform consent process. All of our patients underwent multidisciplinary evaluation before treatment started. The esophageal cancer patients who were in clinical stage IV or inoperable at initial diagnosis were not offered surgical resection of the esophagus. In the cohort of 185 patients, the exclusion criteria for analysis were cancer other than squamous cell carcinoma subtype (n ¼ 10), patients who had esophagectomy as initial treatment (n ¼ 80), and patients who had incomplete CCRT because of intolerance to treatment (n ¼ 1). Accordingly, 94 patients were enrolled in our study (Fig. 1) .
The trimodality treatment strategy consisting of surgery, chemotherapy, and radiation therapy has been carried out in KF-SYSCC since 2000. In 2001, we set up a clinical practice guideline for esophageal cancer. In this guideline, preoperative workup included upper gastrointestinal (UGI) endoscopy with biopsy, computed tomography (CT) scan of the thorax and abdomen, and fusion positron emissionecomputed tomography (PET-CT) scan. In preoperative evaluation, patients with tumor size 5 cm and clinical N0 disease would be treated with upfront surgery (Surgery first, with or without adjuvant therapy). Adjuvant CCRT was given if the gross residual tumor or positive resection margin was found postoperatively. Patients with tumor >5 cm or with clinical N1 disease received induction CCRT first followed by surgery if operable. Patients who had clinical stage IV or inoperable disease received CCRT or palliative care. This practice guideline was minutely changed in 2009, wherein patients with clinical tumor size 3 cm wound received upfront surgery, whereas patients with tumor size >3 cm or with clinical N1 disease would go for neoadjuvant CCRT followed by surgery.
Chemoradiation therapy
We adopted the National Comprehensive Cancer Network clinical practice guidelines to schedule CCRT. Briefly Surgery was performed 8e10 weeks after completion of CCRT. The interval between surgery and CCRT was relatively longer than the average 4e5 weeks in most protocols because, in our policy, we tended to wait until patients were in better general condition (e.g., weight gain, improvement of appetite, subsided adverse effects of CCRT) before performing esophagectomy.
Pathology
After esophagectomy, all specimens were fixed in formalin for pathological examination. The CRM of the tumor region was inked first, and the resected specimens were serially sectioned. Grossly, the tumors in areas closest to the circumferential margin were sampled and submitted in at least two sections for pathological examination. All representative sections were taken, fixed in 10% formalin and embedded in paraffin, then sectioned at 5-mm thickness and stained with hematoxylin and eosin. Under microscopy, the positive CRM was defined as the presence of tumor cells within 1 mm of the inked adventitial tissue edge. At least two pathologists reviewed the slides of all specimens in a blinded fashion. 
Postoperative follow-up
All patients were followed by the operating surgeon and oncologists at regularly scheduled intervals (every 3 months for the first 3 years, every 6 months up to 5 years, and yearly thereafter). Chest X-ray was performed every 3 months, and CT scan of the abdomen and chest was performed every 6 months. PET-CT scan was performed yearly in the first 3 years, and whole body bone scan was performed after 3 years of follow-up. UGI endoscopy was performed whenever patients showed symptoms or signs suspicious for recurrence.
Statistical analysis
Statistical analysis was performed using SPSS version 17.0 software package (SPSS, Chicago, IL, USA). The follow-up time was defined as the period from the date of surgery until patient death or the time of last contact with the patient. Multivariate analyses were performed by Cox regression hazard model for selected prognostic factors that were significant ( p < 0.05) on univariate analysis. Overall survival curves were depicted and compared by the KaplaneMeier method using the log-rank test. All statistical analyses were performed with a two-sided significance level of 0.05.
Results
Clinicopathological characteristics of patients and CRM
Three patients who had positive longitudinal cut-end margins were in the group of patients having upfront surgery, whereas there were no patients with positive longitudinal cutend margin in the study cohort. We have two in-hospital deaths within 30 days after the surgery, with one in the upfront surgery group and one in our study cohort.
The general demographic data of the study cohort, including the CRM, are presented in Table 1 . There were 89 male and five female patients in our study cohort, with a median age of 57 years (range ¼ 39e74 years). The mean and median follow-up periods were 32.0 months and 19.8 (range ¼ 1.0e122.8) months, respectively. The 5-year overall survival was 50.4%. Tumor length was routinely evaluated by UGI endoscopy before treatment started. The mean and median tumor lengths were 5.84 cm and 6.00 cm, respectively. However, the endoscope could not pass through the tumor site to perform this measurement in three patients. Tumor staging (ypStage) was evaluated postoperatively according to the American Joint Committee on Cancer 2002 criteria. We had 19 (20.2%) complete remissions (ypStage 0). Overall, the patients were classified as follows: 12 (12.8%), 40 (42.6%), 18 (19.1%), and five (5.3%) had ypStage I, II, III, and IV of the disease, respectively.
Overall, 17 patients were found to have CRM-positive disease, only one of whom was alive at the end of the follow-up. The 5-year overall survival of CRM-positive disease was 11.8%, and in CRM-negative disease, the 5-year overall survival was 60.1% ( p < 0.001) (Fig. 2) .
Surgery and hospital course
The surgery was performed by two board-certified thoracic surgeons. The surgical approach mainly consisted of the McKeown procedure (three-stage), which was performed in 81 (86.2%) patients. Left or right side thoracoabdominal esophagectomy with intrathoracic anastomosis was performed in 11 patients, transhiatal esophagectomy for lesions of the middle/ lower third of the esophagus in one patient, and the IvoreLewis procedure in one patient. For reconstruction, a gastric tube via either the retrosternal or the posterior mediastinal route was used in 85 cases, left colon reconstruction in eight cases, jejunum reconstruction in one case, and a skin tube in one case. At least two-field lymph node dissection was performed in all patients. The median length of ICU stay was 3 days, and the median total hospital stay was 16 days. 
Failure pattern
Among our cohort, 43 patients (45.7%) were noted to have recurrence during the postsurgical follow-up period. Of these 43 patients, local failure was seen in 16 patients (37.2%), simultaneous local and distant failure in nine patients (20.9%), and distant failure in 36 patients (83.7%). Among the 17 patients with CRM-positive disease, 13 patients had disease recurrence, including 11 (84.6%) patients with local failure, others with distant failure or both. Among the 77 patients with CRM-negative disease, 30 patients were noted to have recurrence, including five (16.7%) patients with local failure, others with distant failure or both. A higher local recurrence rate was seen in patients with CRM-positive disease (84.6%) than in patients with CRM-negative disease (16.7%).
In those patients having recurrence, additional chemotherapy was reserved for those who are medically fit. The dosage and regimens were chosen according to the patients' performance status and their tolerance for drug toxicity. Palliative care was provided for those who could not have chemotherapy. Radiation therapy was not suggested given that those patients had preoperative radiation therapy. Table 2 18 shows the univariate and multivariate analysis of prognostic factors in our cohort. Both ypStage ( p < 0.001) and CRM status ( p < 0.001) were poor prognostic predictors for overall survival in univariate analysis. Age, gender, tumor location (upper/middle/lower third of esophagus), pre-CCRT tumor length, and cell differentiation did not show a statistically significant difference in our cohort. All factors analyzed in univariate analysis were entered into a Cox proportional hazard model for multivariate analysis. The CRM involvement carried a hazard ratio of 3.371 (95% confidence interval, 
Prognostic factors analysis
Discussion
CRM status and survival
The idea of investigating the significance of CRM involvement in esophageal cancer originated from surgical resection of rectal cancer, in which CRM status is an established risk factor for long-term survival. 10 For esophageal cancer, the surgical technique and treatment strategy have evolved over the past decade; however, the survival rate of esophageal cancer remains poor. In the investigation of prognostic factors, the importance of CRM status after esophagectomy has been discussed for decades, but remains controversial. In 1993, Sagar et al 1 raised the idea of an association of a higher local recurrence rate and CRM involvement. We also see this pattern in our study. In 2001, Dexter et al 2 presented the first large-scale study on the impact of CRM involvement on overall survival. Further studies investigating the prognostic significance of CRM supported the idea that CRM involvement is a poor prognostic factor for overall survival; however, there were conflicting results.
3e5 Thompson et al 5 stated that the survival advantage in the CRMnegative group was due to the absence of nodal involvement. Mirnezami et al 4 found that CRM status failed to show significance in multivariate analysis, and thus concluded that CRM involvement is not an independent factor influencing survival in resected esophageal cancer. Khan et al 3 showed that CRM positivity had no detrimental effect on patient survival. Harvin et al, 11 analyzing a group of patients with esophageal ADC after neoadjuvant CCRT, reported that tumors close (<1 mm) to the radial margin did not result in a significant decrease in overall or disease-free survival or increase in local recurrence.
In our study, with a cohort of pure ESCC after preoperative CCRT, we still support the idea that CRM involvement is significantly associated with poor survival after esophagectomy. Although CRM positivity was found in only 17 patients (18.1%) in our cohort, poor survival outcome still showed significance even after adjustment for other associated factors (Table 2 ).
Chemoradiation therapy
The role of chemotherapy and radiation therapy in esophageal cancer has been established in many trials. At present, a combination of chemotherapy and radiation therapy, in addition to surgery, has been included in the treatment guidelines for esophageal cancer. Unlike earlier reports, the studies on CRM also included variable percentages of patients with preoperative chemotherapy.
1e3,6e9, 12 Chao et al 13 first reported that the distance of the tumor from the CRM is associated with local recurrence and survival in patients with ESCC after preoperative CCRT. Saha et al 9 reported that CRM involvement is an independent prognostic factor after multimodal therapy for esophageal ADC. Rao et al 14 also reported that CRM positivity (tumor <1 mm resection margin) significantly predicted poor overall survival. Whether the clinical significance of the CRM differs in patients with or without neoadjuvant therapy is unknown. Khan et al, 15 in reviewing studies of the CRM, concluded that for patients who undergo surgery alone, the prognostic importance of CRM involvement is unclear; however, for patients who undergo preoperative chemotherapy, CRM involvement appears to be an independent predictor of poor long-term survival. The rationale behind this conclusion may be that the neoadjuvant CCRT could significantly reduce CRM involvement, and thus increase the resectability of tumor. 7, 16 A patient who has a positive CRM after neoadjuvant CCRT implies a poor response to CCRT, which predicts a poor survival outcome. Therefore, the CRM status is a strong predictor for overall survival in patients who had neoadjuvant CCRT. However, the conclusion of Khan et al was not based on any clinical trial. To date, there is no evidence to show that the impact of CRM status on survival would differ in patients receiving preoperative CCRT compared with those not receiving preoperative CCRT. In our study, we included patients with esophageal cancer undergoing preoperative CCRT followed by surgery. CRM is a significant prognostic factor in our cohort. The result partly echoed the report of Khan et al. 15 
Panendoscopic tumor length
In our study, pre-CCRT tumor length measured by a UGI endoscope was far from being associated with overall survival. As reported by Gaur et al, 17 patients with preoperative tumor length >2 cm had significantly poorer overall survival compared with patients with tumor length 2 cm. They concluded that the endoscopic esophageal tumor length is an independent prognostic predictor of long-term survival ( p ¼ 0.02). 17 However, their conclusion was based on a cohort of esophageal ADC undergoing esophagectomy without neoadjuvant therapy. In our study with a cohort receiving preoperative CCRT, we did not observe tumor length to be a prognostic factor associated with overall survival. The predicting power of tumor length may be confounded by the effect of CCRT in our cohort. In other words, the survival benefit of this group of patients may rely on their clinical response to CCRT and surgery instead of tumor length.
CRM and other prognostic factors
In a study by Griffiths et al, 6 patients with CRM involvement were more likely to have lymph node metastases, longer tumor length, and more advanced TNM stage. In our cohort, more patients with CRM-positive diseases were seen in advanced ypT status (ypT3 and ypT4), ypN1 status, and advanced overall ypTNM stage. We examined the impact of CRM status on overall survival in patients with ypT3, T4 status (a total of 41 patients), and patients with ypN1 status (a total of 30 patients). In both population subgroups, patients with CRM-negative diseases still had a significantly better overall survival than their counterparts (log rank p ¼ 0.002, and 0.001, respectively). Similarly, more patients with CRMpositive diseases were seen in advanced ypTNM stages (stages III and IV). However, after adjusting for other prognostic factors including ypTNM stage, CRM status remained a significant prognostic factor for overall survival (Table 2 ).
Limitations and strengths of this study
In our study, the absence of a clinically determined stage is considered a weakness. The clinical stage was not included for analysis because the accuracy of the clinical stage was not satisfactory. It may be because endoscopic ultrasound was not used routinely in the evaluation of esophageal cancer in patients in our medical setting. Therefore, the evaluation of tumor depth would be inaccurate. Although the sample size of the present study is relatively small, the cohort of this study is homogenous with ESCC receiving uniform treatment strategy at a single institution. To our knowledge, the significance of CRM in this group of patients has been less discussed in published literatures. Therefore, we believe our data provided a clear description of the clinical significance of CRM in esophageal cancer after preoperative CCRT followed by esophagectomy.
In conclusion, CRM-positive disease in esophageal cancer may represent residual tumor cells, more advanced disease, vulnerability to local recurrence, or poor response to treatment. The prognostic value of a positive CRM should be emphasized. In our study, we concluded that CRM status is a significant prognostic factor for long-term survival in patients with ESCC after trimodality treatment. Additional efforts, such as proper patient selection for CCRT, proper interval between CCRT and surgery, proper radiation dose, and technically doing whatever is necessary to achieve a radical resection of the esophagus, should be made to ensure that a clear CRM is achieved in the treatment of esophageal cancer.
